The Asia Pacific regional market for the manufacture of viral vector vaccines is expected to have CAGR of 18.01% during the forecast period of 2019-2027. Advanced viral vector vaccines for the treatment of chronic and infectious diseases are also expected to boost the growth of the market in the Asia-Pacific region. The strategies adopted by the key market players in Japan and the government initiatives promoting clinical trials in India are the key factors driving growth in the Asia-Pacific viral vector vaccine manufacturing market.

ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURE MARKET FORECAST 2019-2027

Asia Pacific Viral Vector Vaccines Manufacturing Market by Types 2019-2027 (Adenoviral Vectors, Retroviral Vectors, Lent Viral Vectors, Adeno-associated Viral Vectors, Poxvirus, Cytomegalovirus, Other Viral Vectors) by Application (Multivalent, Multipathogen) by Diseases (Human Diseases, Veterinary Diseases) by Geography.

Request free sample

Report Summary

The Asia Pacific regional market for the manufacture of viral vector vaccines is expected to have CAGR of 18.01% during the forecast period of 2019-2027. Advanced viral vector vaccines for the treatment of chronic and infectious diseases are also expected to boost the growth of the market in the Asia-Pacific region.

The strategies adopted by the key market players in Japan and the government initiatives promoting clinical trials in India are the key factors driving growth in the Asia-Pacific viral vector vaccine manufacturing market. The viral vector vaccine manufacturing market is also driven by the government approvals to conduct trials related to the Ebola virus disease vaccine. An increasing number of clinical trials related to viral vector vaccine in China also drives the growth of the viral vector vaccine manufacturing market in this country. Additionally, the high prevalence of avian flu in China is contributing to the increased demand of the viral vector vaccine manufacturing market.

Leading market players in the Asia Pacific viral vector vaccine manufacturing market are Advanced Biotherapeutics Consulting, Advanced Bioscience Laboratories Inc., Biogen Idec (Now Biogen Inc.), Benitec Biopharma, Boehringer Ingelheim Gmbh, Cell And Gene Therapy Catapult, Biovian, Id Pharma Co. Ltd., Ceva Corporate, Cobra Biologics (Subsidiary Of Recip Ab), Applied Viromics, Batavia Biosciences, Brammer Bio, Ge Healthcare and Janssen Pharmaceutical Inc.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • POX VIRUS CONSTITUTES THE LARGEST MARKET SHARE IN TERMS OF TYPES
        • HUMAN DISEASES ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
        • MULTIVALENT APPLICATIONS ARE WIDELY USED IN THE VIRAL VECTOR MANUFACTURING MARKET
    1. MARKET DETERMINANTS
      • MARKET DRIVERS
        • PROMISING RESULTS FROM SEVERAL CLINICAL STUDIES
        • MOUNTING NUMBER OF VIRAL VECTORS GENE-THERAPY-BASED CLINICAL TRIALS
        • GROWING CHRONIC DISEASES
      • MARKET OPPORTUNITIES
        • SWELLING INVESTMENT IN GENE-THERAPY-BASED R&D ACTIVITIES
        • INCREASE IN THE RESEARCH AND DEVELOPMENT
      • MARKET RESTRAINTS
        • POOR REIMBURSEMENT SYSTEM
        • STRINGENT GOVERNMENT POLICIES
      • MARKET CHALLENGES
        • UNFAVOURABLE COMPENSATION SITUATION
        • PRICING PRESSURE COUPLED WITH LACK OF PRODUCT DIFFERENTIATION
        • RIGOROUS REGULATORY AGENDA
    1. MARKET SEGMENTATION
      • MARKET BY TYPES 2019-2027
        • ADENOVIRAL VECTORS
        • RETROVIRAL VECTORS
        • LENTIVIRAL VECTORS
        • ADENO-ASSOCIATED VIRAL VECTORS
        • POXVIRUS
        • CYTOMEGALOVIRUS
        • OTHER VIRAL VECTORS
      • MARKET BY APPLICATION 2019-2027
        • MULTIVALENT
        • MULTIPATHOGEN
      • MARKET BY DISEASES 2019-2027
        • HUMAN DISEASES
          • HEPATITIS
          • CANCER
          • MALARIA
          • TUBERCULOSIS
          • INFLUENZA
          • HIV
          • OTHER HUMAN DISEASES
        • VETERINARY DISEASES
          • AVIAN INFLUENZA
          • MAREK’S DISEASE
          • INFECTIOUS BRONCHITIS
          • PPR DISEASE
          • OTHER VETERINARY DISEASES
    1. KEY ANALYTICS
      • EVOLUTION AND TRANSITION
      • REGULATORY FRAMEWORK
        • ASIA PACIFIC
          • AUSTRALIA
          • JAPAN
          • INDIA
          • CHINA
        • KEY PROPERTIES OF VIRAL VECTOR
        • CHARACTERISTICS OF POTENTIAL VIRAL VACCINE VECTORS
        • PATENT ANALYSIS
          • JAPAN PATENT ANALYSIS
        • MANUFACTURING PROCESS OF A VIRAL-VECTOR
        • SMALL-SCALE MANUFACTURING PROCESS OF ADENOVIRUS
        • KEY SUPPLIERS IN VIRAL VECTOR MARKET
        • KEY BUYING CRITERIA
    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • CHINA
        • INDIA
        • JAPAN
        • AUSTRALIA
        • SOUTH KOREA
        • REST OF ASIA-PACIFIC
    1. COMPANY PROFILES
      • ADVANCED BIOTHERAPEUTICS CONSULTING
      • ADVANCED BIOSCIENCE LABORATORIES INC.
      • APPLIED VIROMICS
      • BATAVIA BIOSCIENCES
      • BENITEC BIOPHARMA
      • BIOGEN IDEC (NOW BIOGEN INC.)
      • BIOVIAN
      • BRAMMER BIO
      • BOEHRINGER INGELHEIM GMBH
      • CELL AND GENE THERAPY CATAPULT
      • CEVA CORPORATE
      • COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)
      • GE HEALTHCARE
      • JANSSEN PHARMACEUTICAL INC.
      • ID PHARMA CO. LTD

    LIST OF TABLES

    TABLE  1      ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)

    TABLE  2      ONGOING CLINICAL TRIALS RELATED TO VIRAL VECTORS

    TABLE  3      VARIOUS VIRAL VECTORS PROPERTIES AND THEIR APPLICATION IN GENE THERAPY

    TABLE  4      ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  5      KEY VIRAL VECTORS CHARACTERISTICS

    TABLE  6      ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENOVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  7      ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN RETROVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  8      ADVANTAGES AND DISADVANTAGES OF RETROVIRAL VECTORS

    TABLE  9      COMPONENTS OF HIV PROVIRUS

    TABLE  10    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN LENTIVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  11    SECOND- VS. THIRD-GENERATION LENTIVIRAL SYSTEMS

    TABLE  12    AAV VECTORS WITH THEIR TROPISMS AND RECEPTORS

    TABLE  13    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENO-ASSOCIATED VIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  14    LICENSED FOWL POX VIRAL-VECTORED VETERINARY VACCINES

    TABLE  15    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN POX VIRUS 2019-2027 ($ THOUSANDS)

    TABLE  16    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN CYTOMEGALOVIRUS 2019-2027 ($ THOUSANDS)

    TABLE  17    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN OTHER VIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  18    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET BY APPLICATION 2019-2027 ($ THOUSANDS)

    TABLE  19    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIVALENT 2019-2027 ($ THOUSANDS)

    TABLE  20    TB STATISTICS FOR 2016

    TABLE  21    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIPATHOGEN 2019-2027 ($ THOUSANDS)

    TABLE  22    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET BY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  23    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  24    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  25    ASIA PACIFIC HUMAN DISEASES  MARKET IN HEPATITIS 2019-2027 ($ THOUSANDS)

    TABLE  26    ESTIMATED ACTUAL NEW CASES OF HAV

    TABLE  27    ASIA PACIFIC HUMAN DISEASES  MARKET IN CANCER 2019-2027 ($ THOUSANDS)

    TABLE  28    ASIA PACIFIC HUMAN DISEASES  MARKET IN MALARIA 2019-2027 ($ THOUSANDS)

    TABLE  29    MALARIA VACCINE DEVELOPMENT INITIATIVES

    TABLE  30    VIRAL VECTOR VACCINE CANDIDATES FOR TUBERCULOSIS

    TABLE  31    ASIA PACIFIC HUMAN DISEASES  MARKET IN TUBERCULOSIS 2019-2027 ($ THOUSANDS)

    TABLE  32    ASIA PACIFIC HUMAN DISEASES  MARKET IN INFLUENZA 2019-2027 ($ THOUSANDS)

    TABLE  33    BENEFITS AND CONCERN FOR VIRUS-VECTORED EXPERIMENTAL INFLUENZA VACCINES

    TABLE  34    ASIA PACIFIC HUMAN DISEASES  MARKET IN HIV 2019-2027 ($ THOUSANDS)

    TABLE  35    ASIA PACIFIC HUMAN DISEASES  MARKET IN OTHER HUMAN DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  36    ONGOING CLINICAL TRIALS AND DEVELOPMENT IN ZIKA VIRUS VACCINE

    TABLE  37    LICENSED VIRAL-VECTORED VETERINARY VACCINES

    TABLE  38    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  39    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES BY TYPES  2019-2027 ($ THOUSANDS)

    TABLE  40    AVIAN INFLUENZA VACCINES

    TABLE  41    ASIA PACIFIC VETERINARY DISEASES MARKET IN AVIAN INFLUENZA 2019-2027 ($ THOUSANDS)

    TABLE  42    ASIA PACIFIC VETERINARY DISEASES MARKET IN MAREK’S DISEASE 2019-2027 ($ THOUSANDS)

    TABLE  43    MAREK’S DISEASE VACCINES

    TABLE  44    ASIA PACIFIC VETERINARY DISEASES MARKET IN INFECTIOUS BRONCHITIS 2019-2027 ($ THOUSANDS)

    TABLE  45    ASIA PACIFIC VETERINARY DISEASES MARKET IN PPR DISEASE 2019-2027 ($ THOUSANDS)

    TABLE  46    ASIA PACIFIC VETERINARY DISEASES MARKET IN OTHER VETERINARY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  47    ASIA-PACIFIC  VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    TABLE  48    CHINA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

    TABLE  49    ONGOING PRECLINICAL AND CLINICAL TRIALS OF HIV/AIDS VACCINE IN CHINA

    TABLE  50    PREVALENCE OF TUBERCULOSIS IN INDIA 2016

    TABLE  51    INDIAVIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

    TABLE  52    CLINICAL TRIALS RELATED TO HIV VACCINE IN INDIA

    TABLE  53    JAPAN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

    TABLE  54    AUSTRALIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

    TABLE  55    SOUTH KOREA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

    TABLE  56    PRINCIPAL CAUSES OF DEATHS IN SINGAPORE, 2014–2016

    TABLE  57    NUMBER OF HIV AND AIDS PEOPLE IN THAILAND 2016

    LIST OF FIGURES

    FIGURE  1    ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)

    FIGURE  2    SCHEMATIC OVERVIEW OF MULTIVALENT AND MULTIPATHOGEN VIRAL VECTOR VACCINES

    FIGURE  3    ESTIMATION OF PEOPLE LIVING WITH HIV 2016 (MILLION)

    FIGURE  4    PREVALENCE OF HBV INFECTION IN THE GENERAL POPULATION 2015 (MILLIONS)

    FIGURE  5    VACCINE ADVANCEMENTS TIMELINE

    FIGURE  6    STEPS REQUIREMENT FOR VACCINE APPROVAL

    FIGURE  7    VACCINE REVIEW AND REGULATION STEPS UNDER MHLW

    FIGURE  8    APPROVAL PROCESS OF VACCINE IN INDIA

    FIGURE  9    MANUFACTURING PROCESS OF ADENOVIRUS

    FIGURE  10  CHINA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  11  INDIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  12  JAPAN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  13  NUMBER OF HIV CASES IN JAPAN 2012 AND 2016

    FIGURE  14  AUSTRALIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  15  VARIOUS VIRAL VACCINE VECTORS USED IN AIDS VACCINE DEVELOPMENT

    FIGURE  16  NUMBER OF DIAGNOSED HIV INFECTIONS IN AUSTRALIA 2012–2016

    FIGURE  17  SOUTH KOREA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  18  SHARES OF DEATH IN SOUTH KOREA IN 2016 DEATH RATE (PER 100,000 POPULATIONS)

    FIGURE  19  REST OF ASIA-PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • CHINA
        • INDIA
        • JAPAN
        • AUSTRALIA
        • SOUTH KOREA
        • REST OF ASIA-PACIFIC
    1. MARKET SEGMENTATION
      • MARKET BY TYPES 2019-2027
        • ADENOVIRAL VECTORS
        • RETROVIRAL VECTORS
        • LENTIVIRAL VECTORS
        • ADENO-ASSOCIATED VIRAL VECTORS
        • POXVIRUS
        • CYTOMEGALOVIRUS
        • OTHER VIRAL VECTORS
      • MARKET BY APPLICATION 2019-2027
        • MULTIVALENT
        • MULTIPATHOGEN
      • MARKET BY DISEASES 2019-2027
        • HUMAN DISEASES
          • HEPATITIS
          • CANCER
          • MALARIA
          • TUBERCULOSIS
          • INFLUENZA
          • HIV
          • OTHER HUMAN DISEASES
        • VETERINARY DISEASES
          • AVIAN INFLUENZA
          • MAREK’S DISEASE
          • INFECTIOUS BRONCHITIS
          • PPR DISEASE

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      RELATED REPORTS